Catalog No.
Product Name
Application
Product Information
Citations
-
Wnt Pathway Inhibitor
Wnt Pathway Inhibitor 5 is a potent inhibitor of the Wnt signaling pathway, exhibiting an IC50 value of less than 0.003 µM. This compound demonstrates significant anti-cancer activity, making it effective against various malignancies such as ovarian teratocarcinoma, breast cancer, osteosarcoma, and head and neck squamous carcinoma. It serves as a valuable tool for researchers investigating the role of Wnt signaling in cancer progression and therapeutic interventions. -
Wnt Activator
XD23 is a potent Wnt activator that functions by downregulating DKK1, thereby enhancing the WNT/β-catenin signaling pathway. This compound demonstrates significant biological activity in osteosarcoma inhibition, making it a valuable tool for research into bone cancer and related signaling mechanisms. Its ability to modulate Wnt signaling opens avenues for investigating therapeutic strategies targeting Wnt-related pathways in various cancers. -
Wnt/β-catenin Pathway Inhibitor
IWP-2-V2 is an analogue of IWP-2 that effectively inhibits the Wnt/β-catenin signaling pathway. This compound plays a significant role in modulating cellular processes related to development and cancer, making it a valuable tool for researchers studying the implications of Wnt signaling in various biological contexts. Its ability to disrupt β-catenin-mediated transcriptional activity positions IWP-2-V2 as a potential candidate for investigations into regenerative medicine and cancer therapy. -
Wnt Signaling Activator
BML-284 hydrochloride is a potent Wnt signaling activator that enhances TCF-dependent transcriptional activity. It demonstrates an effective EC50 of 700 nM, making it suitable for researching Wnt pathway modulation. This compound is valuable for studies related to developmental biology, cancer research, and other fields that investigate the role of Wnt signaling in cellular processes. -
Wnt Pathway Inhibitor
SEN461 is a potent and orally bioavailable inhibitor of the Wnt signaling pathway. This compound demonstrates significant anti-tumor activity, making it a valuable tool for research applications in glioblastoma multiforme (GBM) and other cancers driven by aberrant Wnt pathway activation. Its efficacy in modulating Wnt-related processes highlights its potential for therapeutic development and mechanistic studies in cancer biology. -
Wnt/b-catenin Inhibitor
21H7 is a selective inhibitor of the Wnt/β-catenin signaling pathway. This compound significantly inhibits cell proliferation in hair follicles and demonstrates potent growth suppression of breast and colon cancer cells. Due to its specific targeting of the Wnt/β-catenin pathway, 21H7 serves as a valuable tool in cancer research and therapeutic development. -
β-Catenin Inhibitor
β-Catenin-IN-7 is an inhibitor of β-catenin, specifically disrupting the interaction between β-catenin and Tcf-4. This compound effectively inhibits Wnt-dependent target gene expression, demonstrating significant anti-cancer activity. It is a valuable tool for research applications focused on cancer biology and the Wnt signaling pathway. -
Wnt Signal Inhibitor
Wnt/β-catenin-IN-7 is a Wnt signaling pathway inhibitor with an IC50 of 0.15 μM. This compound effectively disrupts β-catenin-mediated transcriptional activation, making it valuable for investigating the role of Wnt signaling in cancer and fibrosis. Its potent inhibitory activity supports research into therapeutic targets within these pathological conditions. -
β-catenin Inhibitor
PMED-1 is a potent β-catenin inhibitor that effectively diminishes β-catenin activity in hepatoblastoma and various hepatocellular carcinoma (HCC) cell lines, exhibiting an IC50 range of 4.87 to 32 μM. This compound disrupts Wnt signaling by reducing the interaction between β-catenin and CREB binding protein, leading to the inhibition of cell proliferation. PMED-1 is a valuable tool for cancer research, particularly in studies focused on targeting aberrant Wnt signaling pathways. -
Wnt/β-catenin Inhibitor
Wnt/β-catenin-IN-4 is a potent inhibitor of the Wnt/β-catenin signaling pathway. This compound effectively disrupts β-catenin-dependent transcription, making it a valuable tool for investigating the role of Wnt signaling in various biological processes. It is commonly utilized in cancer research, developmental biology, and studies related to stem cell differentiation. -
WNT5A Antagonist
MDGCEL is a WNT5A peptide that functions as an antagonist to WNT5A signaling. It mimics WNT5A, providing utility in research focused on modulating WNT signaling pathways. MDGCEL is valuable in studies investigating developmental biology, cell signaling, and cancer research, where the regulation of WNT5A activity is crucial. -
Hedgehog Inhibitor
Hh Pathway-IN-1 is a potent inhibitor of the Hedgehog (Hh) signaling pathway, acting primarily as a Gli antagonist. With an IC50 value of 1.1 µM in C3H10T1/2 cells, it demonstrates significant inhibition of Hh pathway functionality while sparing Wnt signaling. Hh Pathway-IN-1 exhibits anti-proliferative effects and reduces GLI1 mRNA expression, contributing to its efficacy in inhibiting colony formation in a dose-dependent manner. This compound is valuable for research in developmental biology and cancer therapeutics targeting the Hedgehog pathway. -
Hedgehog Pathway Inhibitor
3-epi-Vitamin D3, also known as Epicholecalciferol, functions as a Hedgehog pathway inhibitor, exhibiting an IC50 value of 39.2 μM in U87MG cell lines. This Vitamin D3 analogue is useful in studies investigating the modulation of the Hedgehog signaling pathway, which plays a critical role in cellular growth and differentiation. 3-epi-Vitamin D3 may have potential applications in cancer research, particularly in contexts where Hedgehog dysregulation is implicated. -
Hedgehog Inhibitor
Hedgehog IN-1 is a potent inhibitor of the Hedgehog signaling pathway, demonstrating an IC50 of 70 nM. This compound effectively blocks Hedgehog protein activity, making it valuable for research into developmental biology and cancer therapeutics. Hedgehog IN-1 is instrumental in studies aimed at understanding the role of the Hedgehog pathway in tumorigenesis and potential therapeutic applications in related disorders. -
Hh-Signaling Pathway Antagonist
SANT 2 is a potent antagonist of the Hedgehog (Hh) signaling pathway, specifically inhibiting the expression of Gli1. This compound has been shown to induce developmental delays in medaka embryos, making it a valuable tool for studying embryonic development. SANT 2 has significant research applications in various malignancies, including Gorlin syndrome, as well as prostate, pancreatic, and breast cancers, thereby aiding in the exploration of targeted therapies for these conditions. -
Hh Pathway Inhibitor
T-1330 is an inhibitor of the Hedgehog (Hh) signaling pathway, specifically targeting the downstream effector Gli1. By effectively reducing Gli1 expression, T-1330 plays a crucial role in modulating Hh pathway activity. This compound is useful in research applications related to developmental biology and cancer therapy, particularly in studies investigating aberrant Hh signaling in various malignancies. -
Smoothened/Hedgehog Antagonist
AZD8542 is a potent Smoothened (SMO) antagonist that effectively disrupts the Hedgehog (Hh) signaling pathway, which is crucial in tumor progression. This compound is particularly relevant in oncology research, focusing on the interactions within the tumor microenvironment and the stroma compartment. AZD8542's ability to inhibit Hh pathway activity makes it a valuable tool in the study of cancer therapies and tumor biology. -
Hedgehog Pathway Antagonist
Smo antagonist M25 is a selective inhibitor of the Smoothened (Smo) receptor within the Hedgehog signaling pathway. By blocking Smo activity, it effectively attenuates the downstream effects of Hedgehog signaling, which plays a crucial role in cell proliferation and differentiation. This compound is primarily utilized in research applications focusing on cancer biology, developmental processes, and potential therapeutic interventions associated with aberrant Hedgehog pathway activation. -
Hedgehog Pathway Inhibitor
Hedgehog IN-2 is a potent inhibitor of the Hedgehog signaling pathway, exhibiting an IC50 value of less than 0.003 μM in C3H10T1/2 cells. This compound effectively disrupts Hedgehog-mediated cellular signaling, making it a valuable tool for studying embryonic development, cancer biology, and regenerative medicine. Its high potency and specificity enable researchers to investigate the role of the Hedgehog pathway in various biological processes and disease states. -
Hedgehog Inhibitor
Hedgehog IN-6 is a potent Hedgehog (Hh) inhibitor that targets the Hh signaling pathway by binding to the cysteine-rich domain (CRD) of Smoothened (Smo). By obstructing the cholesterization of Smo, Hedgehog IN-6 effectively inhibits Hh pathway activation, which is crucial in various cancer types. This compound is valuable for research applications aimed at understanding and manipulating Hh signaling in oncogenesis and developmental biology. -
Hedgehog Pathway Inhibitor
HPP-9 is a Hedgehog Pathway inhibitor designed as a Proteolysis-Targeting Chimera (PROTAC) that effectively degrades BET bromodomains. With a pIC50 of 6.71, HPP-9 exhibits significant antitumor activity. This compound is valuable for research applications focused on cancer biology and the modulation of the Hedgehog signaling pathway. -
Hedgehog Pathway Inhibitor
Hedgehog IN-3 is a potent inhibitor of the Hedgehog signaling pathway, exhibiting an IC50 of 0.01 µM. This compound is primarily utilized in cancer research to investigate the role of Hedgehog-mediated signaling in tumorigenesis and cellular proliferation. Its effectiveness in modulating this pathway makes it a valuable tool for studying various malignancies and developing targeted therapeutic strategies. -
Hedgehog Inhibitor
Hedgehog IN-10 is a potent inhibitor of the Hedgehog signaling pathway, targeting essential components in cellular signaling. This compound demonstrates significant antitumor activity, making it a valuable tool for cancer research. Its ability to modulate Hedgehog signaling contributes to investigations into therapeutic strategies for tumors associated with dysregulated Hedgehog pathway activity. -
Hh Inhibitor
Physalin H is a bioactive compound extracted from Solanum nigrum, functioning as a Hedgehog (Hh) signaling inhibitor. It effectively disrupts GLI1-DNA complex formation and inhibits GLI1 transcription with an IC50 of 0.7 μM. Additionally, Physalin H exhibits cytotoxic effects on PANC1 and DU145 cancer cell lines, demonstrating IC50 values of 5.7 μM and 6.8 μM, respectively. This compound is valuable for research into Hh pathway modulation and cancer therapeutics. -
Hedgehog Pathway Inhibitor
Hedgehog IN-5 is a small molecule inhibitor that targets the Hedgehog signaling pathway. This orally active compound is primarily employed in research pertaining to fibrotic diseases, providing valuable insights into the mechanisms underlying this condition. Its ability to modulate Hedgehog pathway activity makes it a significant tool for exploring therapeutic strategies in related biological contexts. -
Hedgehog Antagonist
Methoxy-SANT-2 is a potent Hedgehog pathway antagonist, demonstrating an IC50 value of 79.8 nM. It effectively inhibits Gli1 reporter gene expression, making it a valuable tool in investigating Hedgehog signaling. This compound is suitable for research applications focused on cancer biology and therapeutic strategies targeting the Hedgehog pathway. -
Hedgehog Inhibitor
Hedgehog IN-4 is a potent inhibitor of the Hedgehog signaling pathway, acting as a benzamide derivative with an IC50 of 0.050 nM. It effectively disrupts Hedgehog-mediated cellular processes, making it valuable for research on developmental biology, cancer, and regenerative medicine. Its ability to modulate this critical pathway allows for exploration into the mechanisms of diseases associated with Hedgehog signaling dysregulation. -
PKG Inhibitor
Protein kinase G inhibitor-1 is a selective inhibitor targeting protein kinase G (PKG) with an IC50 of 0.9 μM. This compound is utilized primarily in research related to mycobacterial infections, providing insights into the mechanisms of pathogenesis and potential therapeutic approaches. Its efficacy in inhibiting PKG activity makes it a valuable tool for exploring mycobacterial biology and developing novel treatments. -
PKC Substrate
Myelin Basic Protein (MHP4-14) serves as a specific substrate for protein kinase C (PKC), demonstrating a Km of 7 μM. This synthetic peptide, derived from residues 4-14 of myelin basic protein, is not phosphorylated by various other kinases, including cyclic AMP-dependent protein kinase and casein kinases I and II. It is highly effective for studying PKC activity in crude tissue extracts, providing a low background and reliable results in biochemical assays. -
PI4Kβ/PKG Inhibitor
PI4Kβ/PKG-IN-2 is a potent dual inhibitor targeting Plasmodium phosphatidylinositol 4-kinase beta (PI4Kβ) and cGMP-dependent protein kinase (PKG). This compound demonstrates significant inhibitory activity against Plasmodium, making it a valuable tool for investigating malaria pathogenesis and potential therapeutic strategies. Its oral bioavailability further supports its use in preclinical studies aimed at understanding malaria biology. -
PfGSK3/PfPK6 Inhibitor
PfGSK3/PfPK6-IN-1 is a selective inhibitor targeting PfGSK3 and PfPK6, with IC50 values of 97 nM and 8 nM, respectively. This compound effectively inhibits the proliferation of blood-stage Plasmodium falciparum 3D7 parasites, making it a valuable tool for malaria research. Additionally, PfGSK3/PfPK6-IN-1 exhibits low cytotoxicity in hepatocyte cultures at concentrations up to 200 nM, with a significant reduction in cell viability observed at 2 μM. Its dual action enhances its potential in studying malaria-related mechanisms and potential therapeutic strategies. -
Stable Isotope
Nicotinamide-d3 is a deuterium-labeled form of Nicotinamide, a vital derivative of vitamin B3. It functions primarily by inhibiting SIRT1 and SIRT2 activity, with an IC50 of 2 μM for SIRT2. Biological studies show that Nicotinamide-d3 enhances cellular levels of NAD+, ATP, and reactive oxygen species (ROS), exhibiting potential anti-tumor effects and improved survival outcomes in various contexts. Additionally, this compound is recognized for its anti-hepatitis B virus (HBV) activity, making it valuable for research in metabolism and cancer biology. -
PKG Inhibitor
Protein kinase G inhibitor-2 is a selective inhibitor of mycobacterial protein kinase G, exhibiting an IC50 value of 3 μM. This compound is utilized in the investigation of mycobacterial infections and their associated signaling pathways. Its efficacy as a PKG inhibitor supports research into therapeutic strategies targeting mycobacterial diseases. -
Molecular Glue Degrader
WEE1 Degrader 1 is a CRBN-dependent molecular glue degrader that targets WEE1 and casein kinase 1α (CK1α) with sub-2 nM DC50 values for both proteins. This compound effectively induces the proteasomal degradation of its targets, providing a valuable tool for studying cell cycle regulation. WEE1 Degrader 1 is particularly relevant in the research of acute lymphoblastic leukemia, acute monocytic leukemia, acute promyelocytic leukemia, colorectal adenocarcinoma, and diffuse large B-cell lymphoma. -
Prostaglandin Analog
Prostaglandin E1 ethanolamide is a prostaglandin analog that primarily targets the GLI2 signaling pathway. This compound has been shown to inhibit GLI2-induced expression of downstream genes such as Gli1 and Ptch1, demonstrating its potential in regulating tumor growth. As a valuable tool for cancer research, Prostaglandin E1 ethanolamide may facilitate investigations into therapeutic strategies that disrupt GLI2-mediated oncogenic processes. -
PKG Activator
Dibutyryl-cGMP sodium is a cell-permeable analogue of cyclic guanosine monophosphate (cGMP) that primarily activates cGMP-dependent protein kinase (PKG). This compound has been shown to inhibit the release of [3H]-arachidonic acid from γ-thrombin-stimulated human platelets, demonstrating its role in modulating platelet activity. Additionally, Dibutyryl-cGMP sodium induces peripheral antinociception through the activation of ATP-sensitive potassium channels, making it a valuable tool for research in pain modulation and cardiovascular physiology. -
PKG Activator
8-Bromo-cGMP sodium is a membrane-permeable analogue of cyclic guanosine monophosphate (cGMP) that acts as a potent activator of protein kinase G (PKG). This compound has been shown to significantly inhibit Ca2+ macroscopic currents and to impair high potassium-induced insulin release. Additionally, 8-Bromo-cGMP sodium exhibits antinociceptive properties and elicits vasodilatory responses, making it valuable for studies investigating cardiovascular and metabolic functions. -
Gamma-Secretase Modulator
γ-Secretase modulator 13 is a gamma-secretase modulator that inhibits the production of the aggregated amyloid β-peptide Aβ42, exhibiting an IC50 value of 163 nM. This compound is valuable for research in Alzheimer's disease, facilitating investigations into amyloidogenic processes and potential therapeutic interventions. Its specific modulation of γ-secretase activity positions it as a significant tool for studying the mechanisms underlying neurodegenerative disorders. -
YAP Inhibitor
Hirudin (54-65) is a potent thrombin antagonist and YAP inhibitor that exhibits anticoagulatory properties. By blocking the anion binding site of thrombin, it inhibits both soluble and thrombus-bound thrombin, subsequently reducing YAP expression, nuclear translocation, and downstream signaling in vascular endothelial cells. This compound is employed in research related to liver obstructive cholestasis and liver fibrosis, as it ameliorates fibrosis symptoms, attenuates angiogenesis, and decreases inflammation and tissue hypoxia. Furthermore, Hirudin (54-65) promotes extracellular calcium influx in vascular smooth muscle, facilitating endothelium-independent contraction. -
Gli1-DNA Interaction Inhibitor
Glabrescione B is a Gli1-DNA interaction inhibitor that targets the Hedgehog (Hh) signaling pathway. This compound disrupts the activity of Gli1 by preventing its binding to DNA, thereby inhibiting the growth of Hedgehog-dependent tumor cells. Additionally, Glabrescione B impairs the self-renewal capacity and clonogenic potential of tumor-derived stem cells, making it a valuable tool for studying Hh-related cancers and stem cell biology. -
3MST Inhibitor
I3MT-3 is a selective inhibitor of 3-Mercaptopyruvate sulfurtransferase (3MST), exhibiting an IC50 value of 2.7 μM, demonstrating its potency against this target. The compound selectively interacts with a persulfurated cysteine residue within the active site of 3MST, ensuring minimal off-target activity. I3MT-3 is ideal for studies investigating the role of hydrogen sulfide and its metabolic pathways, as well as potential therapeutic applications related to sulfur metabolism. -
MST1 Inhibitor
IHMT-MST1-58 is a potent and selective inhibitor of the mammalian STE20-like protein 1 kinase (MST1), demonstrating an IC50 value of 23 nM. This compound is valuable for investigating the role of MST1 in cellular signaling pathways and can be utilized in research focused on Type 1 and Type 2 diabetes. Its oral bioavailability makes it suitable for in vivo studies aimed at elucidating the therapeutic potential of targeting MST1 in metabolic disorders. -
3-MST Inhibitor
BRD2577 is a selective inhibitor of mercaptopyruvate sulfurtransferase (3-MST) with an IC50 value of 9.9 μM. This compound effectively reduces hydrogen sulfide (H2S) production in colon carcinoma cells, providing insights into the metabolic pathways associated with this cancer type. While BRD2577 shows minimal impact on colon cancer cell proliferation and mitochondrial function, it serves as a valuable tool for investigating the role of H2S in colon cancer biology and therapeutic strategies. -
MST3 Inhibitor
JA310 is a selective MST3 kinase inhibitor, demonstrating high cellular potency with an EC50 value of 106 nM. This compound serves as a valuable tool in studying MST3's role in cellular signaling pathways and its involvement in various diseases. JA310 can be utilized in research applications focused on the modulation of MST3 activity and its effects on cell proliferation, survival, and migration. -
MST3/4 Inhibitor
MR24 is a selective inhibitor of mammalian STE20-like kinases MST3 and MST4. It demonstrates an EC50 of 57 nM for MST3 and 583 nM for MST4, highlighting its targeted activity. MR24 induces G1 phase cell cycle arrest, making it a valuable tool for investigating cell cycle regulation. This compound is particularly relevant for cancer research, including studies focused on breast, liver, and lung cancers. -
ALK4/5/7 Inhibitor
A 83-01 sodium is a selective inhibitor of the transforming growth factor-beta (TGF-β) type I receptors ALK4, ALK5, and ALK7. With IC50 values of 12 nM, 45 nM, and 7.5 nM, it effectively blocks transcriptional activity induced by these kinases. This compound is valuable for research applications focused on TGF-β signaling pathways and regulation of cellular processes such as proliferation, differentiation, and epithelial-mesenchymal transition. -
PKG Inhibitor
Rp-8-pCPT-cGMPS sodium is a selective inhibitor of cGMP-dependent protein kinase (cGK), functioning primarily through the modulation of cGMP signaling pathways. This compound also acts as an agonist for cyclic nucleotide-gated (CNG) channels in a voltage-dependent manner, making it valuable for studying the intricate roles of cyclic nucleotides in cellular processes. Its applications extend to research in cardiovascular physiology, neurobiology, and signal transduction mechanisms. -
PKG Agonist
8-pCPT-cGMP-AM is a potent prodrug that serves as an agonist for protein kinase G (PKG). This compound exhibits high membrane permeability, allowing for efficient intracellular conversion to its active form, 8-pCPT-cGMP, through esterase hydrolysis. 8-pCPT-cGMP-AM is utilized in research focusing on cGMP signaling pathways related to neural plasticity and memory formation, providing valuable insights into cognitive processes. -
PKG1α Activator
PKG1α activator 3 is a selective activator of Protein Kinase G Iα (PKG1α), exhibiting EC50 values of 13 μM for basal activation and 0.52 μM for partial activation. This compound demonstrates significant anti-proliferative effects on smooth muscle cells, making it a valuable tool for investigating mechanisms underlying cardiovascular diseases. Its ability to modulate PKG1α activity positions it as a potential candidate for research focused on vascular function and related pathologies. -
PKG1α Inhibitor
DT-3 is a selective inhibitor of protein kinase G Iα (PKG Iα), designed to impede the cGMP-PKG signaling pathway. This membrane-permeable peptide demonstrates significant pharmacological activity, making it valuable for research applications focused on cardiovascular function and signaling related diseases. DT-3 enables the investigation of the roles of PKG Iα in various cellular processes and helps elucidate its contributions to cardiovascular health and disease.
